PTO/SB/31 (09-06) Approved for use through 03/31/2007. OMB 0651-0031

Approved to use intugin distribution. Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OME control number.

	Under the Paperw	ork Reduction Act of 1995, no persons a	re required to respon	nd to a collection			
NOTICE OF APPEAL FROM THE EXAMINER TO					Docket Number (Optional)		
THE BOARD OF PATENT APPEALS AND INTERFERENCES					17007-CON		
I hereby certify that this correspondence is being e-filed via the USPTO Electronic Filing System (EFS) on the date shown below.							
FEBRUARY 14, 2007				Application Number 09/845/514		Filed APRIL 30, 2001	
-	(ADDIANIE CIDEDOON)			For MULTIPLE BOTULINUM TOXINS FOR TREATING NEUROMUSCULAR DISORDERS AND CONDITIONS			
Signature				Art Unit	Exa	Examiner	
Type	d or printed A	DRIANE GIBERSON		1645	F	ORD, VANESSA L.	
Applicant hereby appeals to the Board of Patent Appeals and Interferences from the last decision of the examiner.							
The fee for this Notice of Appeal is (37 CFR 41.20(b)(1)) \$_500.00							
Applicant claims small entity status. See 37 CFR 1.27. Therefore, the fee shown above is reduced by half, and the resulting fee is:							
A check in the amount of the fee is enclosed.							
Payment by gredit card. Form PTO-2038 is attached.							
The Director has already been authorized to charge fees in this application to a Deposit Account. I have enclosed a duplicate copy of this sheet.							
The Director is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. 01-0895 . I have enclosed a duplicate copy of this sheet.							
A petition for an extension of time under 37 CFR 1.136(a) (PTO/SB/22) is enclosed.							
WARNING: Information on this form may become public. Credit eard information should not be included on this form. Provide credit card information and authorization on PTO-2038.							
I am the							
	applicant/inventor.				/CLAUDE L. NASSIF/		
	assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)			Claude L. Nassif, Ph.D.			
				Typed or printed name			
	attorney or agent of record. Registration number				714-246-6458		
					Telepho	one number	
V	attorney or agent acting under 37 CFR 1.34. Registration number if acting under 37 CFR 1.34. 52,061			FEBRUARY 14, 2007			
						Date	
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.							

This collection of information is required by 37 CFR 41.31. The information is required to obtain or retain a benefit by the public which is to the (and by the USPTO to process) an application. Confidentially is governed by \$5 U.S.C. 123 and 37 CFR 11.11.11.14 and 41.61. This collection is estimated to less 12 minuses to compare, neuroung gentreing, preparing, and suprinting time compared application from to the USPTO. Time were very appearance upon the innovation reason. Any comments on the anomator fitters upon require to complete this form and/or suggestions for redding this burden. Anchald be sent to the information Office. U.S. Papeart and Trademark Office, U.S. Department of the compared to the control of the USPTO Comments of the Comment of the unique of the USPTO Comments of the USPTO Comments of the USPTO Comment OF THE USPTO CO

*Total of

forms are submitted.